Yousif Capital Management LLC Sells 10,883 Shares of Medtronic PLC $MDT

Yousif Capital Management LLC cut its stake in Medtronic PLC (NYSE:MDT) by 3.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 275,120 shares of the medical technology company’s stock after selling 10,883 shares during the quarter. Yousif Capital Management LLC’s holdings in Medtronic were worth $26,202,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in MDT. Intergy Private Wealth LLC raised its holdings in Medtronic by 22.3% in the third quarter. Intergy Private Wealth LLC now owns 3,578 shares of the medical technology company’s stock worth $341,000 after purchasing an additional 652 shares in the last quarter. Farther Finance Advisors LLC boosted its holdings in shares of Medtronic by 1.1% in the 3rd quarter. Farther Finance Advisors LLC now owns 67,742 shares of the medical technology company’s stock valued at $6,452,000 after buying an additional 756 shares in the last quarter. Leonard Rickey Investment Advisors P.L.L.C. grew its position in shares of Medtronic by 3.3% in the 3rd quarter. Leonard Rickey Investment Advisors P.L.L.C. now owns 5,022 shares of the medical technology company’s stock worth $478,000 after buying an additional 161 shares during the last quarter. Parcion Private Wealth LLC raised its stake in shares of Medtronic by 9.7% during the 3rd quarter. Parcion Private Wealth LLC now owns 3,621 shares of the medical technology company’s stock worth $345,000 after acquiring an additional 321 shares in the last quarter. Finally, Patton Fund Management Inc. purchased a new stake in Medtronic during the third quarter valued at approximately $249,000. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

Medtronic Stock Performance

Shares of MDT stock opened at $97.71 on Tuesday. Medtronic PLC has a 52-week low of $79.29 and a 52-week high of $106.33. The company has a quick ratio of 1.80, a current ratio of 2.42 and a debt-to-equity ratio of 0.57. The stock has a market cap of $125.26 billion, a PE ratio of 26.34, a price-to-earnings-growth ratio of 2.60 and a beta of 0.71. The business has a 50-day simple moving average of $97.42 and a 200-day simple moving average of $93.54.

Medtronic (NYSE:MDT) last posted its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share for the quarter, beating the consensus estimate of $1.31 by $0.05. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The firm had revenue of $8.96 billion during the quarter, compared to analyst estimates of $8.86 billion. During the same period in the previous year, the firm earned $1.26 EPS. The business’s quarterly revenue was up 6.6% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, equities analysts expect that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, January 16th. Investors of record on Friday, December 26th will be given a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a dividend yield of 2.9%. The ex-dividend date is Friday, December 26th. Medtronic’s dividend payout ratio is 76.55%.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on MDT. Barclays upped their price target on Medtronic from $109.00 to $111.00 and gave the stock an “overweight” rating in a research report on Thursday, November 20th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Medtronic in a research report on Monday, December 15th. The Goldman Sachs Group set a $111.00 price target on Medtronic and gave the company a “neutral” rating in a research note on Wednesday, November 19th. Sanford C. Bernstein set a $111.00 price target on Medtronic in a research note on Wednesday, November 19th. Finally, Piper Sandler restated a “neutral” rating on shares of Medtronic in a report on Friday, November 14th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and twelve have issued a Hold rating to the company. According to data from MarketBeat, Medtronic has an average rating of “Moderate Buy” and an average target price of $109.94.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).